Natalia Żak
Research Subjects
Research Interests
Natalia Żak has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aldona Pażyra
Mazowiecki Szpital Wojewódzki im. św. Jana Pawła II w Siedlcach located at 26 Poniatowskiego Street, 08-110 Siedllce
9 shared publications - Barbara Jaworska
Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Lublinie located at 3 Grenadierów Street; 20-331 Lublin
9 shared publications - Natalia Kusak
Students’ Research Group at the Department of Toxicology, Medical University of Lublin
9 shared publications - Paweł Stanicki
Student Research Group at the I Department of Psychiatry, Psychotherapy and Early Intervention , Medical University of Lublin , Poland
7 shared publications - Julita Szarpak
Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie located at 100 Kraśnicka Avenue, 20-718 Lublin
3 shared publications - Aleksandra Błaszczyk
Collegium Medicum Uniwersytetu Jana Kochanowskiego
2 shared publications
Latest Publications
- Open Access
- 25 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 23
The effects of antioxidants on various body systems and physical activity - a literature review on Astaxanthin
Astaxanthin is an organic fat-soluble compound from the xanthophyll group derived mainly from marine organisms. It has greater antioxidant properties than vitamins e, c and beta-carotene. It may have potential applications in various areas of medicine and dietetics. The safe daily dose appears to be 6-8 mg per day. Its use may be beneficial in cardiology by lowering insulin resistance, improving lipid profile and reducing the extent of myocardial infarction. In addition, it improves cognitive function and has beneficial effects on skin properties such as texture and hydration. Its positive effects on visual acuity have also been proven. Its use can increase fat burning during aerobic exercise and increase physical performance during exercise. Considering the available research results, astaxanthin seems to be a promising supplement with strong antioxidant properties. Most of the studies, however, were conducted on animals and more human studies are needed. The purpose of this work is to summarize the available knowledge regarding this unique substance. The article reviews studies and scientific papers available in PubMed databases on Astaxanthin for the period 2010-2023.
- 25 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 23
Open AccessThe effects of antioxidants on various body systems and physical activity - a literature review on Astaxanthin
Astaxanthin is an organic fat-soluble compound from the xanthophyll group derived mainly from marine organisms. It has greater antioxidant properties than vitamins e, c and beta-carotene. It may have potential applications in various areas of medicine and dietetics. The safe daily dose appears to be 6-8 mg per day. Its use may be beneficial in cardiology by lowering insulin resistance, improving lipid profile and reducing the extent of myocardial infarction. In addition, it improves cognitive function and has beneficial effects on skin properties such as texture and hydration. Its positive effects on visual acuity have also been proven. Its use can increase fat burning during aerobic exercise and increase physical performance during exercise. Considering the available research results, astaxanthin seems to be a promising supplement with strong antioxidant properties. Most of the studies, however, were conducted on animals and more human studies are needed. The purpose of this work is to summarize the available knowledge regarding this unique substance. The article reviews studies and scientific papers available in PubMed databases on Astaxanthin for the period 2010-2023.
- Open Access
- 21 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54285
The multifaceted role of long non-coding RNA DLEU1 in cancer progression: implications for diagnosis and therapy
INTRODUCTION AND PURPOSE: Long non-coding RNAs are key regulators of gene expression and tumorigenesis. Deleted in leukemia 1 (DLEU1) is significant in cancer development. This article reviews DLEU1's role across cancers, assessing its diagnostic and therapeutic potential. METHODS: A review of scientific articles from PubMed and Google Scholar was conducted. DESCRIPTION OF THE STATE OF KNOWLEDGE: DLEU1 drives tumor growth in glioblastoma, esophageal, colorectal, and oral cancers by interacting with key miRNAs and genes, promoting malignancy. In breast and ovarian cancers, DLEU1 modulates migration and invasion via specific pathways. In cervical cancer, DLEU1 is linked to immune modulation and serves as a prognostic marker. SUMMARY: DLEU1 is a vital regulator in various cancers, offering potential as a diagnostic and therapeutic target.
- 21 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54285
Open AccessThe multifaceted role of long non-coding RNA DLEU1 in cancer progression: implications for diagnosis and therapy
INTRODUCTION AND PURPOSE: Long non-coding RNAs are key regulators of gene expression and tumorigenesis. Deleted in leukemia 1 (DLEU1) is significant in cancer development. This article reviews DLEU1's role across cancers, assessing its diagnostic and therapeutic potential. METHODS: A review of scientific articles from PubMed and Google Scholar was conducted. DESCRIPTION OF THE STATE OF KNOWLEDGE: DLEU1 drives tumor growth in glioblastoma, esophageal, colorectal, and oral cancers by interacting with key miRNAs and genes, promoting malignancy. In breast and ovarian cancers, DLEU1 modulates migration and invasion via specific pathways. In cervical cancer, DLEU1 is linked to immune modulation and serves as a prognostic marker. SUMMARY: DLEU1 is a vital regulator in various cancers, offering potential as a diagnostic and therapeutic target.
- Open Access
- 20 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54679
Will melatonin supplementation become a new form of obesity treatment? A review of recent literature.
Background: In 2020, the World Health Organization (WHO) estimated that 650 million adults worldwide are obese, and 2.8 billion individuals struggle with overweight. Obesity is associated with an increased risk of cardiovascular diseases, type 2 diabetes, heart disease, adverse effects on mental health, the development of certain cancers, and other conditions. In recent years, there has been growing interest in the role of melatonin, which has therapeutic potential in the treatment of obesity. Studies suggest that melatonin supplementation may lead to weight reduction and improvement in metabolic parameters, significantly reduce cardiovascular disease risk factors, and enhance insulin sensitivity in obese individuals. Aim of study: This review aims to present the latest scientific findings on the impact of melatonin supplementation on the development of obesity and its complications. We focus primarily on the mechanisms of melatonin's action in the context of obesity, particularly on potential pathways that have not yet been thoroughly explored. Our aim is to provide deeper insights into research on obesity and its prevention. Materials and Methods: Search was conducted using PubMed and Google Scholar databases, utilizing the keywords "obesity," "melatonin," and "weight loss" in various configurations. The review primarily considers studies published after 2016 that are available online. Summary Melatonin supplementation leads to a statistically significant reduction in blood glucose levels and an increase in cellular insulin sensitivity. Its promising properties in the treatment of obesity have been demonstrated through the reduction of oxidative stress, indicating a potential adjunct for weight loss. Based on the cited studies, the beneficial effects of melatonin supplementation on cardiovascular risk factors have been confirmed. Melatonin could be considered as an adjunctive therapy for obese individuals who do not respond to other treatment modalities.
- 20 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54679
Open AccessWill melatonin supplementation become a new form of obesity treatment? A review of recent literature.
Background: In 2020, the World Health Organization (WHO) estimated that 650 million adults worldwide are obese, and 2.8 billion individuals struggle with overweight. Obesity is associated with an increased risk of cardiovascular diseases, type 2 diabetes, heart disease, adverse effects on mental health, the development of certain cancers, and other conditions. In recent years, there has been growing interest in the role of melatonin, which has therapeutic potential in the treatment of obesity. Studies suggest that melatonin supplementation may lead to weight reduction and improvement in metabolic parameters, significantly reduce cardiovascular disease risk factors, and enhance insulin sensitivity in obese individuals. Aim of study: This review aims to present the latest scientific findings on the impact of melatonin supplementation on the development of obesity and its complications. We focus primarily on the mechanisms of melatonin's action in the context of obesity, particularly on potential pathways that have not yet been thoroughly explored. Our aim is to provide deeper insights into research on obesity and its prevention. Materials and Methods: Search was conducted using PubMed and Google Scholar databases, utilizing the keywords "obesity," "melatonin," and "weight loss" in various configurations. The review primarily considers studies published after 2016 that are available online. Summary Melatonin supplementation leads to a statistically significant reduction in blood glucose levels and an increase in cellular insulin sensitivity. Its promising properties in the treatment of obesity have been demonstrated through the reduction of oxidative stress, indicating a potential adjunct for weight loss. Based on the cited studies, the beneficial effects of melatonin supplementation on cardiovascular risk factors have been confirmed. Melatonin could be considered as an adjunctive therapy for obese individuals who do not respond to other treatment modalities.
- Open Access
- 17 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54341
Congenital CMV infection - what we know about the symptoms, treatment and prevention? - Review of literature
Introduction: Cytomegalovirus (CMV) is a double-strand DNA virus, member of the viral family known as Herpesviridae which is wide-spread. CMV infection is the most common congenital infection worldwide. Disease is mostly asymptomatic for healthy people, therefore is detected late, when the children start presenting symptoms. Unfortunately the congenital CMV infection leads to the serious health problems for infants. Detection of the virus is typically done through quantitative PCR assays. Infection especially affects nervous system and can present infant’s deafness. Earlier it was equivalent with the children being deaf till the end of life, but nowadays thanks to the development of laryngological methods (ex. cochlear implantation) patients have chance to grow up correctly. Material and methods: A literature search was conducted using Google Scholar, PubMed, and Web of Science databases. We searched articles by entering key words in the appropriate configuration: “CMV”, “Congenital CMV infection”, “valganciclovir”, “infant’s deafness”. Scientific articles published between 1991–2023 were analyzed from all over the world and guidelines of Polish Society of Epidemiology and Infectious Diseases.Conclusions: Currently we haven’t got prevention towards congenital CMV, only the treatment for infants: valganciclovir. It stops development of severe symptoms. There are available analysis, where using valganciclovir during pregnancy reduces the possibility or soften the course of the congenital CMV infection , but it’s not the obligatory guidelines. In many countries researchers want to conduct screening test for CMV IgG among the pregnant women.
- 17 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54341
Open AccessCongenital CMV infection - what we know about the symptoms, treatment and prevention? - Review of literature
Introduction: Cytomegalovirus (CMV) is a double-strand DNA virus, member of the viral family known as Herpesviridae which is wide-spread. CMV infection is the most common congenital infection worldwide. Disease is mostly asymptomatic for healthy people, therefore is detected late, when the children start presenting symptoms. Unfortunately the congenital CMV infection leads to the serious health problems for infants. Detection of the virus is typically done through quantitative PCR assays. Infection especially affects nervous system and can present infant’s deafness. Earlier it was equivalent with the children being deaf till the end of life, but nowadays thanks to the development of laryngological methods (ex. cochlear implantation) patients have chance to grow up correctly. Material and methods: A literature search was conducted using Google Scholar, PubMed, and Web of Science databases. We searched articles by entering key words in the appropriate configuration: “CMV”, “Congenital CMV infection”, “valganciclovir”, “infant’s deafness”. Scientific articles published between 1991–2023 were analyzed from all over the world and guidelines of Polish Society of Epidemiology and Infectious Diseases.Conclusions: Currently we haven’t got prevention towards congenital CMV, only the treatment for infants: valganciclovir. It stops development of severe symptoms. There are available analysis, where using valganciclovir during pregnancy reduces the possibility or soften the course of the congenital CMV infection , but it’s not the obligatory guidelines. In many countries researchers want to conduct screening test for CMV IgG among the pregnant women.
- Open Access
- 29 August 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 21
Neurological complications of infective endocarditis - a review
Introduction and purpose Infective endocarditis (IE) is a disease resulting from infection of the endocardium. In addition to cardiac symptoms, frequent complications of IE include various damage to the nervous system. The aim of this study is to describe the current state of knowledge about the neurological complications of infective endocarditis. Methods Medical publications were reviewed using the "PubMed" and "Google Scholar" databases. The obtained results were verified in terms of the following criteria: publication in 2016, retrospective analysis, obtaining 44 papaers covering a total of 8067 patients. The information was supplemented with case reports and meta-analyses. Description of the state of knowledge Neurologic complications occur in 20 to 60% of patients with IE. The most common is ischemic stroke, the symptoms of which may precede the diagnosis of IE. Less common complications that often remain asymptomatic include mycotic aneurysms and intracranial hemorrhages. Infectious material entering the brain may also cause meningitis and brain abscess. However, these complications do not occur often. Magnetic resonance imaging of the head is an effective test for detecting neurological damage in the course of IE. The recommendation for routine use of this test is debatable. In addition to antibiotic therapy, cardiac surgery is used to treat IE to remove bacterial vegetation. Research indicates the high effectiveness of this type of surgery in the prevention and treatment of neurological complications of infective endocarditis.
- 29 August 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 21
Open AccessNeurological complications of infective endocarditis - a review
Introduction and purpose Infective endocarditis (IE) is a disease resulting from infection of the endocardium. In addition to cardiac symptoms, frequent complications of IE include various damage to the nervous system. The aim of this study is to describe the current state of knowledge about the neurological complications of infective endocarditis. Methods Medical publications were reviewed using the "PubMed" and "Google Scholar" databases. The obtained results were verified in terms of the following criteria: publication in 2016, retrospective analysis, obtaining 44 papaers covering a total of 8067 patients. The information was supplemented with case reports and meta-analyses. Description of the state of knowledge Neurologic complications occur in 20 to 60% of patients with IE. The most common is ischemic stroke, the symptoms of which may precede the diagnosis of IE. Less common complications that often remain asymptomatic include mycotic aneurysms and intracranial hemorrhages. Infectious material entering the brain may also cause meningitis and brain abscess. However, these complications do not occur often. Magnetic resonance imaging of the head is an effective test for detecting neurological damage in the course of IE. The recommendation for routine use of this test is debatable. In addition to antibiotic therapy, cardiac surgery is used to treat IE to remove bacterial vegetation. Research indicates the high effectiveness of this type of surgery in the prevention and treatment of neurological complications of infective endocarditis.
- Open Access
- 26 August 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 21, 54089
Kallmann Syndrome - causes, symptoms, treatment - review of literature
Background: Kallmann syndrome is a rare congenital disorder characterized by hypogonadotropic hypogonadism and anosmia or hyposmia. KS results from abnormalities in the migration of GnRH neurons from the nasal placode to the hypothalamus. The prevalence of KS is estimated to be approximately 1:30,000 in males and 1:125,000 in females. KS manifests at various stages of life, ranging from the neonatal period through adolescence to adulthood. In the neonatal period, boys may present with cryptorchidism and micropenis, while symptoms in girls may be less apparent. During adolescence, patients often experience the absence or incomplete development of secondary sexual characteristics. In adulthood, KS often leads to infertility, cardiovascular issues, and neurological symptoms. Diagnostic methods include olfactory tests and hormonal analysis, assessing levels of gonadotropins, testosterone, LH and FSH. MRI can reveal structural abnormalities in the olfactory system. Aim of study: The goal of this article was to gather information about the Kallmann syndrome, focusing on its epidemiology, etiology, characteristic features, and treatment strategies. Materials and Methods: A review of the literature available in the “PubMed”, Google Scholar and Medline databases. The search was performed by using following keywords: “kallmann syndrome”, “anosmia”, hypogonadotropic hypogonadism”. Results and conclusions: Kallmann syndrome is a complex condition that necessitates a multifaceted approach to diagnosis and treatment. Early identification of the disorder is crucial, allowing for the timely initiation of appropriate hormonal therapy and psychological support, which significantly improves the quality of life for patients. Further research into the genetic and neurobiological mechanisms of KS is essential for the development of more effective therapeutic and diagnostic methods.
- 26 August 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 21, 54089
Open AccessKallmann Syndrome - causes, symptoms, treatment - review of literature
Background: Kallmann syndrome is a rare congenital disorder characterized by hypogonadotropic hypogonadism and anosmia or hyposmia. KS results from abnormalities in the migration of GnRH neurons from the nasal placode to the hypothalamus. The prevalence of KS is estimated to be approximately 1:30,000 in males and 1:125,000 in females. KS manifests at various stages of life, ranging from the neonatal period through adolescence to adulthood. In the neonatal period, boys may present with cryptorchidism and micropenis, while symptoms in girls may be less apparent. During adolescence, patients often experience the absence or incomplete development of secondary sexual characteristics. In adulthood, KS often leads to infertility, cardiovascular issues, and neurological symptoms. Diagnostic methods include olfactory tests and hormonal analysis, assessing levels of gonadotropins, testosterone, LH and FSH. MRI can reveal structural abnormalities in the olfactory system. Aim of study: The goal of this article was to gather information about the Kallmann syndrome, focusing on its epidemiology, etiology, characteristic features, and treatment strategies. Materials and Methods: A review of the literature available in the “PubMed”, Google Scholar and Medline databases. The search was performed by using following keywords: “kallmann syndrome”, “anosmia”, hypogonadotropic hypogonadism”. Results and conclusions: Kallmann syndrome is a complex condition that necessitates a multifaceted approach to diagnosis and treatment. Early identification of the disorder is crucial, allowing for the timely initiation of appropriate hormonal therapy and psychological support, which significantly improves the quality of life for patients. Further research into the genetic and neurobiological mechanisms of KS is essential for the development of more effective therapeutic and diagnostic methods.
- Open Access
- 2 August 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 17, 53388
Preeclampsia - the leading cause of maternal and neonatal mortality in the world - review of literature
Background: This review analyzes current knowledge on the pathophysiology, prevention and art of treatment of preeclampsia. Preeclampsia (known as EPH-gestosis) is nowadays the leading cause of maternal and neonatal mortality in the world. According to statistics it affects up to 5% of pregnant women. The symptoms are high blood pressure, edema, proteinuria. The scientists all over the world are trying their best to know the pathogenesis to devise a cure for the disease. Aim of study: The goal of this article was to gather information about the pathophisiology and treatment of preeclempsia to prevent the risk of ilness’ development. Materials and methods: A review of the literature available in the “PubMed”, Google Scholar and Medline databases. The search was performed by using following keywords: “preeclampsia”, “ophthalmic artery doppler”, “PIGF”, “aspirin”, “placenta”. Results and conclusions: In spite of the progress of science the preeclampsia is still a serious threat for pregnant women all around the world. Thank to the advanced molecular and ultrasonographic techniques the doctors can estimate the risk of complications. The most important is screening, which helps the doctors to define the group of risk and then launch the treatment. That should decrease the amount of maternal and neonatal complications and deaths.
- 2 August 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 17, 53388
Open AccessPreeclampsia - the leading cause of maternal and neonatal mortality in the world - review of literature
Background: This review analyzes current knowledge on the pathophysiology, prevention and art of treatment of preeclampsia. Preeclampsia (known as EPH-gestosis) is nowadays the leading cause of maternal and neonatal mortality in the world. According to statistics it affects up to 5% of pregnant women. The symptoms are high blood pressure, edema, proteinuria. The scientists all over the world are trying their best to know the pathogenesis to devise a cure for the disease. Aim of study: The goal of this article was to gather information about the pathophisiology and treatment of preeclempsia to prevent the risk of ilness’ development. Materials and methods: A review of the literature available in the “PubMed”, Google Scholar and Medline databases. The search was performed by using following keywords: “preeclampsia”, “ophthalmic artery doppler”, “PIGF”, “aspirin”, “placenta”. Results and conclusions: In spite of the progress of science the preeclampsia is still a serious threat for pregnant women all around the world. Thank to the advanced molecular and ultrasonographic techniques the doctors can estimate the risk of complications. The most important is screening, which helps the doctors to define the group of risk and then launch the treatment. That should decrease the amount of maternal and neonatal complications and deaths.
- Open Access
- 10 July 2024
- Published by Medical Education in OncoReview
- Vol. 14 (2(54)) , 34-37
An extremely rare case of atypical fibroxanthoma – case report
The first clinical case of atypical fibroxanthoma was documented in 1958, and to date, approximately 3,000 patients have been described in the literature with this diagnosis. Furthermore, the recurrence rate or potential for metastasis in atypical fibroxanthoma is estimated to be as low as 2%. It is noteworthy that fibroxanthoma most commonly arises in the head and neck region. Therefore, the clinical case presented here of a patient diagnosed with atypical fibroxanthoma on the left earlobe margin, with suspected disease recurrence after approximately one year, is extremely rare, so we believed it is noticeable to report.
- 10 July 2024
- Published by Medical Education in OncoReview
- Vol. 14 (2(54)) , 34-37
Open AccessAn extremely rare case of atypical fibroxanthoma – case report
The first clinical case of atypical fibroxanthoma was documented in 1958, and to date, approximately 3,000 patients have been described in the literature with this diagnosis. Furthermore, the recurrence rate or potential for metastasis in atypical fibroxanthoma is estimated to be as low as 2%. It is noteworthy that fibroxanthoma most commonly arises in the head and neck region. Therefore, the clinical case presented here of a patient diagnosed with atypical fibroxanthoma on the left earlobe margin, with suspected disease recurrence after approximately one year, is extremely rare, so we believed it is noticeable to report.
- Open Access
- 18 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 69, 49174
Therapeutic Potential of Vitamin D in Asthma Control
In 2019, according to WHO estimates, 262 million people were affected by asta, resulting in 455,000 deaths. Asthma, is a chronic inflammatory disease of the airways that causes reversible bronchoconstriction, making it difficult for patients to breathe. Exacerbations of the disease can be caused by a variety of factors but share similar symptoms such as wheezing, coughing, shortness of breath and chest tightness. Severe asthma exacerbations are defined as symptoms that do not respond to inhaled medications and improve only after oral or intravenous steroid administration. Asthma-related deaths often occur during exacerbations. Vitamin D, which is produced naturally in the body and found in some foods, is a steroid-derived vitamin. Adequate doses of this vitamin, administered through medication or supplements, can be used to maintain its proper levels in the organism. Vitamin D is essential for regulating calcium levels in the body and for bone remodeling. It also has immunomodulatory effects, affecting both innate and adaptive immunity. This partly explains its association with changes in the airway epithelium that occur as a result of inflammation in asthma. The study aims to summarize the current knowledge on the relationship of vitamin D with asthma symptom control. The present study is based on literature available in scientific databases from 2013-2016, such as PubMed, Corchane Library and Google Scholar, using the following keywords: "vitamin D" and "asthma." Vitamin D deficiency is prevalent in children and adults worldwide. A critical analysis of the literature reveals that the therapeutic administration of vitamin D has no apparent advantage in treating asthma, especially in children. Nevertheless, for adults with mild asthma, vitamin D supplementation shows promise for improved outcomes. However, there is a pressing need for large-scale clinical trials to determine the efficacy and safety of this therapeutic approach for both age groups.
- 18 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 69, 49174
Open AccessTherapeutic Potential of Vitamin D in Asthma Control
In 2019, according to WHO estimates, 262 million people were affected by asta, resulting in 455,000 deaths. Asthma, is a chronic inflammatory disease of the airways that causes reversible bronchoconstriction, making it difficult for patients to breathe. Exacerbations of the disease can be caused by a variety of factors but share similar symptoms such as wheezing, coughing, shortness of breath and chest tightness. Severe asthma exacerbations are defined as symptoms that do not respond to inhaled medications and improve only after oral or intravenous steroid administration. Asthma-related deaths often occur during exacerbations. Vitamin D, which is produced naturally in the body and found in some foods, is a steroid-derived vitamin. Adequate doses of this vitamin, administered through medication or supplements, can be used to maintain its proper levels in the organism. Vitamin D is essential for regulating calcium levels in the body and for bone remodeling. It also has immunomodulatory effects, affecting both innate and adaptive immunity. This partly explains its association with changes in the airway epithelium that occur as a result of inflammation in asthma. The study aims to summarize the current knowledge on the relationship of vitamin D with asthma symptom control. The present study is based on literature available in scientific databases from 2013-2016, such as PubMed, Corchane Library and Google Scholar, using the following keywords: "vitamin D" and "asthma." Vitamin D deficiency is prevalent in children and adults worldwide. A critical analysis of the literature reveals that the therapeutic administration of vitamin D has no apparent advantage in treating asthma, especially in children. Nevertheless, for adults with mild asthma, vitamin D supplementation shows promise for improved outcomes. However, there is a pressing need for large-scale clinical trials to determine the efficacy and safety of this therapeutic approach for both age groups.
- Open Access
- 9 January 2024
- Published by Medical Education in OncoReview
- Vol. 13 (4(52)) , 99-102
Intraocular Metastasis of Small Cell Lung Cancer: A Case Report
We report a rare case of intraocular metastasis of small cell lung cancer with disease progression.
- 9 January 2024
- Published by Medical Education in OncoReview
- Vol. 13 (4(52)) , 99-102
Open AccessIntraocular Metastasis of Small Cell Lung Cancer: A Case Report
We report a rare case of intraocular metastasis of small cell lung cancer with disease progression.